Bergmann, Natasha C.

Semaglutide for the treatment of overweight and obesity: A review

Bergmann, N. C., Davies, M. J., Lingvay, I., & Knop, F. K. (2023) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals.

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Jensen, M. H., Gabe, M. B. N., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., et al. (2019) · Diabetes

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 193

Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study

Bergmann, N. C., Lund, A., Gasbjerg, L. S., Meessen, E. C. E., Andersen, M. M., Bergmann, S., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., et al. (2019) · Diabetologia

Regulation of Appetite and ObesityDiabetes Treatment and Management

Cited by 142

Evaluation of the incretin effect in humans using GIP and GLP-1 receptor antagonists

Gasbjerg, L. S., Bergmann, N. C., Stensen, S., Christensen, M. B., Rosenkilde, M. M., Holst, J. J., Nauck, M., & Knop, F. K. (2020) · Peptides

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 121

The effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review

Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 80

GIP and GLP-1 receptor antagonism during a meal in healthy individuals

Gasbjerg, L. S., Helsted, M. M., Hartmann, B., Sparre-Ulrich, A. H., Veedfald, S., Stensen, S., Lanng, A. R., Bergmann, N. C., Christensen, M. B., Vilsbøll, T., et al. (2020) · The Journal of Clinical Endocrinology & Metabolism

Diabetes Treatment and ManagementPancreatic function and diabetes

Cited by 68

Glucose-dependent insulinotropic polypeptide (GIP) and cardiovascular disease

Heimbürger, S. M., Bergmann, N. C., Augustin, R., Gasbjerg, L. S., Christensen, M. B., & Knop, F. K. (2020) · Peptides

Adipokines, Inflammation, and Metabolic DiseasesDiabetes Treatment and Management

Cited by 67

No Acute Effects of Exogenous Glucose-Dependent Insulinotropic Polypeptide on Energy Intake, Appetite, or Energy Expenditure When Added to Treatment With a Long-Acting Glucagon-Like Peptide 1 Receptor Agonist in Men With Type 2 Diabetes

Bergmann, N. C., Gasbjerg, L. S., Heimbürger, S. M., Krogh, L. S. L., Dela, F., Hartmann, B., Holst, J. J., Jessen, L., Christensen, M. B., Vilsbøll, T., et al. (2020) · Diabetes Care

Diabetes Treatment and ManagementRegulation of Appetite and Obesity

Cited by 62

Incidence rate of symptomatic painless thyroiditis presenting with thyrotoxicosis in Denmark as evaluated by consecutive thyroid scintigraphies

Schwartz, F., Bergmann, N., Zerahn, B., & Faber, J. (2013) · Scandinavian Journal of Clinical and Laboratory Investigation

Thyroid Disorders and TreatmentsThyroid Cancer Diagnosis and Treatment

Cited by 32